A mechanistic theory to explain the efficacy of antiretroviral therapy (Q43721565)

26 November 2017

1 reference

title

A mechanistic theory to explain the efficacy of antiretroviral therapy (English)

1 reference

26 November 2017

2

Robert F Siliciano

1 reference

26 November 2017

1

Sarah B Laskey

1 reference

PubMed ID

25263222

26 November 2017

language of work or name

English

0 references

publication date

29 September 2014

1 reference

Nature Reviews Microbiology

26 November 2017

1 reference

26 November 2017

12

1 reference

26 November 2017

11

1 reference

26 November 2017

772-780

1 reference

https://scigraph.springernature.com/pub.10.1038/nrmicro3351

26 November 2017

0 references

cites work

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The challenge of finding a cure for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Recent trends in HIV-1 drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

A quantitative basis for antiretroviral therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Twenty-five years of translational medicine in antiretroviral therapy: promises to keep

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Decay characteristics of HIV-1-infected compartments during combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Absence of detectable HIV-1 viremia after treatment cessation in an infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

The choreography of HIV-1 proteolytic processing and virion assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Mathematical models of HIV pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

A novel method for determining the inhibitory potential of anti-HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Defining treatment failure in resource-rich settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Antiretroviral dynamics determines HIV evolution and predicts therapy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Once daily dosing improves adherence to antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

No Evidence for Evolution of Protease Inhibitor Resistance from Standard Genotyping, After Three Years of Treatment with Darunavir/Ritonavir, With or Without Nucleoside Analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Raltegravir in the management of HIV-infected patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO3351

Update of the drug resistance mutations in HIV-1: March 2013.

31 March 2020

1 reference

12 December 2020

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

12 December 2020

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

1 reference

12 December 2020

HIV-1 antiretroviral drug therapy

1 reference

12 December 2020

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

1 reference

12 December 2020

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

12 December 2020

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRMICRO3351

1 reference

PubMed ID

25263222

Dimensions Publication ID

26 November 2017

0 references

1 reference

PubMed ID

25263222